Amylx Pharmaceuticals Inc vs Duolingo Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.66 (market cap $2.64B), while Duolingo Inc trades at $135.32 (market cap $6.34B). The key difference: Duolingo Inc is far larger — about 2.4× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | DUOL | |
|---|---|---|
Market Cap | $2.64B | $6.34B |
Sector | Health | Technology |
52-Week High | $24.19 | $369.19 |
52-Week Low | $7.82 | $90.03 |
Enterprise Value | $2.39B | $5.11B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Duolingo (DUOL) trades at $132.75, down 3.24% over 24 hours, with a bullish technical outlook from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.66 versus $0.604 expected, driven by 23% daily active user growth. Revenue reached $1.04 billion in 2025, with net income surging to $414 million, though Q3 2026 revenue guidance fell short of expectations, causing recent stock pressure.
The investment outlook is mixed: robust user growth and profitability metrics like a 35.87% net margin support upside, but decelerating bookings growth and margin pressures from AI investments pose risks. Analysts show cautious optimism with a $121 consensus target, highlighting the stock's sensitivity to monetization trends amid competitive threats.
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →